Tesamorelin (10mg)

What is Tesamorelin?

Tesamorelin is a synthetic 44–amino acid peptide designed as an analogue of human growth hormone–releasing hormone (GHRH). This tesamorelin peptide has been studied in controlled laboratory settings for its role in endocrine signaling and growth hormone regulation. It is not a naturally occurring peptide but a structurally modified version intended to improve stability during experimental use.

• Peptide Sequence: Trans-3-hexenoyl-YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH2

The peptide has a reported molecular weight of 5136 g/mol, depending on salt form, and is commonly supplied as a lyophilized powder with ≥99% purity, verified by HPLC and mass spectrometry. Tesamorelin is typically evaluated in research environments focused on metabolic and hormonal pathway investigation rather than therapeutic application.

What are the key features of Tesamorelin?

Tesamorelin is supplied as a research-grade peptide designed to support reproducible laboratory workflows. Researchers who buy tesamorelin typically do so for in vitro or preclinical experimentation where peptide integrity and analytical validation are essential. Key features include:

• ≥99% purity, confirmed by HPLC and MS
• Supplied as a lyophilized powder in sealed vial format
• Available in standardized presentations, including a tesamorelin 10 mg vial
• Structurally modified to improve resistance to enzymatic degradation
• Suitable for endocrine and metabolic research models
• Manufactured under controlled conditions with batch-level quality documentation
• For laboratory research use only.

How is Tesamorelin synthesized?

Tesamorelin is synthesized using solid-phase peptide synthesis (SPPS), a widely accepted method for producing high-purity research peptides. Individual amino acids are sequentially assembled on a resin backbone to ensure correct sequence fidelity across the full 44–amino acid chain. Following synthesis, the peptide undergoes an N-terminal modification with trans-3-hexanoic acid, a structural change that enhances stability relative to native GHRH. The final product is purified using reverse-phase HPLC, with mass spectrometry employed to confirm identity and molecular weight. This process ensures tesamorelin for research applications meets analytical and reproducibility standards expected in laboratory settings.

What is Tesamorelin being studied for? What are its possible benefits?

Tesamorelin is under investigation in research areas related to endocrine regulation and metabolic signaling. Studies examining the tesamorelin GH peptide focus on how modulation of growth hormone release influences downstream biological markers in controlled experimental models. Primary research areas include:

• Growth hormone secretion dynamics and pulsatility
• IGF-1 signaling and downstream metabolic pathways
• Lipid metabolism and energy balance markers
• Endocrine feedback mechanisms within the GH/IGF axis
• Hormone-responsive cellular signaling pathways

These areas reflect exploratory research findings only. Observed effects are context-dependent and limited to laboratory and preclinical models, with no conclusions regarding clinical outcomes.

How does Tesamorelin work in research studies?

In laboratory studies, tesamorelin is thought to act by stimulating endogenous growth hormone release through interaction with GHRH-sensitive signaling pathways. This process has been associated with increased intracellular signaling activity related to hormone synthesis and regulated secretion. Researchers studying tesamorelin peptide activity have reported downstream changes in growth hormone–responsive biomarkers, including IGF-1, within experimental systems. Importantly, tesamorelin is used to examine physiological hormone regulation mechanisms rather than to replace endogenous hormones, making it useful for studying feedback-controlled endocrine pathways in research environments.

What dosing information exists for Tesamorelin?

Available dosing data for tesamorelin originate from preclinical animal studies and in vitro experiments. In animal models, tesamorelin has been studied at weight-based doses ranging approximately from 0.3 to 1 µg/kg, depending on study design and research endpoints. Cell-based assays typically evaluate tesamorelin at concentrations in the nanomolar to low micromolar range, adjusted for receptor expression and assay sensitivity. While clinical literature describes specific dosing in regulated settings, there are no established human dosing guidelines for research-grade material. Any experimental use of tesamorelin for research should follow peer-reviewed protocols or institutional standards.

How should Tesamorelin be stored and handled?

Lyophilized tesamorelin should be stored at 2–8 °C, protected from light, moisture, and temperature fluctuations. Under these conditions, stability data indicate the peptide can remain within specification for extended periods when unopened. After reconstitution, solutions should be stored at 2–8 °C and used within a short-term window defined by the diluent and handling protocol, commonly 7–14 days. Repeated freeze–thaw cycles should be avoided. Standard laboratory precautions—aseptic handling, proper labeling, and protective equipment—are recommended when working with tesamorelin peptide materials.

Where can I read more research about Tesamorelin?

Researchers interested in additional peer-reviewed data on tesamorelin can consult the following credible scientific sources:

1. Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. doi:10.1001/jama.2014.8334
2. Zhou F, Zhang H, Cong Z, et al. Structural basis for activation of the growth hormone-releasing hormone receptor. Nat Commun. 2020;11(1):5205. Published 2020 Oct 15. doi:10.1038/s41467-020-18945-0
3. National Library of Medicine. Tesamorelin. PubMed. Published 2012. https://www.ncbi.nlm.nih.gov/books/NBK548730/
4. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-4304. doi:10.1210/jc.2010-0490

These publications discuss tesamorelin’s biochemical properties, endocrine signaling effects, and experimental research findings in controlled settings.

Compliance Statement

This product is intended for laboratory research use only and is not approved for human or veterinary use.